MX2024009448A - Formas cristalinas de un inhibidor de mcl-1. - Google Patents

Formas cristalinas de un inhibidor de mcl-1.

Info

Publication number
MX2024009448A
MX2024009448A MX2024009448A MX2024009448A MX2024009448A MX 2024009448 A MX2024009448 A MX 2024009448A MX 2024009448 A MX2024009448 A MX 2024009448A MX 2024009448 A MX2024009448 A MX 2024009448A MX 2024009448 A MX2024009448 A MX 2024009448A
Authority
MX
Mexico
Prior art keywords
crystalline forms
mcl
inhibitor
amg
disclosed
Prior art date
Application number
MX2024009448A
Other languages
English (en)
Spanish (es)
Inventor
Mary Chaves
Robert P Farrell
Stephan Parent
Jing Teng
Lingyun Xiao
Ron C Kelly
Darren L Reid
James E Huckle
Markian Stec
Tian Wu
Michal Achmatowicz
Van Luu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2024009448A publication Critical patent/MX2024009448A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2024009448A 2022-02-04 2023-02-03 Formas cristalinas de un inhibidor de mcl-1. MX2024009448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306776P 2022-02-04 2022-02-04
PCT/US2023/012251 WO2023150249A1 (en) 2022-02-04 2023-02-03 Crystalline forms of an mcl-1 inhibitor

Publications (1)

Publication Number Publication Date
MX2024009448A true MX2024009448A (es) 2024-08-15

Family

ID=85570021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009448A MX2024009448A (es) 2022-02-04 2023-02-03 Formas cristalinas de un inhibidor de mcl-1.

Country Status (7)

Country Link
US (1) US20250115622A1 (cg-RX-API-DMAC10.html)
EP (1) EP4472984A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505141A (cg-RX-API-DMAC10.html)
AU (1) AU2023216691A1 (cg-RX-API-DMAC10.html)
CA (1) CA3246092A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024009448A (cg-RX-API-DMAC10.html)
WO (1) WO2023150249A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119255998A (zh) 2022-05-04 2025-01-03 吉利德科学公司 特定mcl-1抑制剂的盐和多晶型物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
JP7873057B2 (ja) * 2020-03-31 2026-06-11 アムジエン・インコーポレーテツド Mcl-1化合物のメチル化

Also Published As

Publication number Publication date
US20250115622A1 (en) 2025-04-10
AU2023216691A1 (en) 2024-07-04
JP2025505141A (ja) 2025-02-21
WO2023150249A1 (en) 2023-08-10
EP4472984A1 (en) 2024-12-11
CA3246092A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
CO2021014022A2 (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
DOP2023000091A (es) Composiciones de inhibidores peptídicos del receptor de interleucina-23
SV2002000121A (es) Compuestos indazol y composiciones farmaceuticas para inhibir la proteina quinasas y metodo para su uso
CO2019012473A2 (es) Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos
CL2024004051A1 (es) Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y métodos de uso.
ECSP066473A (es) 42-ester de rapamicina amorfo con el ácido 3-hidroxi-2-(hidroximetil)-2-metil propiónico y las composiciones farmaceúticas que contienen el mismo
CL2023000193A1 (es) Inductores químicos de degradación conjugados con anticuerpo de brm y métodos de estos.
ECSP088311A (es) Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urológicos
MX2023000501A (es) Antagonistas del receptor del factor liberador de corticotropina.
MX2024009650A (es) Sal cristalina y formas de solvato de murizatoclax (amg 397).
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
CO2025009897A2 (es) Degradadores de irak y usos de los mismos
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
MX2024013980A (es) Conjugados de glucocorticoides y anticuerpos contra el factor de necrosis tumoral alfa humano
CO2024017533A2 (es) Composiciones de genoterapia y métodos de uso de las mismas
PE20191789A1 (es) Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa
MX2022011455A (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso.
UY27413A1 (es) Agonistas de la oxitocina
MX2025012360A (es) Derivados de pirrolopiridina como moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
ES2114188T3 (es) Uso de antagonistas de los esteroides para el tratamiento y profilaxis de las enfermedades de demencia.
MX2024012192A (es) Formas de sal y solvatos de antagonistas de mci-1
ES2112832T3 (es) Derivados carbamoilicos.
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
GT200500319A (es) Algunos metabolitos derivados de [1,4]diazepino[6,7,1-ij]quinolina y metodos para la preparacion y usos de los mismos.
BR112022003310A2 (pt) Ube3a para tratamento de síndrome de angelman